• SPX
  • $5,740.87
  • 0.72 %
  • $40.93
  • DJI
  • $42,182.36
  • 0.41 %
  • $170.76
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,287.38
  • 0.06 %
  • $4.86
  • IXIC
  • $18,125.73
  • 1.16 %
  • $207.26
Molecular Partners AG (MOLN) Stock Price, News & Analysis

Molecular Partners AG (MOLN) Stock Price, News & Analysis

Currency in USD Disclaimer

$4.58

-$0.09

(-1.93%)

Day's range
$4.58
Day's range
$4.6
50-day range
$4.37
Day's range
$12.22
  • Country: CH
  • ISIN: US60853G1067
52 wk range
$3.32
Day's range
$12.7
  • CEO: Dr. Patrick Amstutz Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 4.26
  • Piotroski Score 4.00
  • Grade Neutral
  • Symbol (MOLN)
  • Company Molecular Partners AG
  • Price $4.58
  • Changes Percentage (-1.93%)
  • Change -$0.09
  • Day Low $4.58
  • Day High $4.60
  • Year High $12.70

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 10/31/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $29.00
  • High Stock Price Target $29.00
  • Low Stock Price Target $29.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.00
  • Trailing P/E Ratio -2.03
  • Forward P/E Ratio -2.03
  • P/E Growth -2.03
  • Net Income $-61,984,000

Income Statement

Quarterly

Annual

Latest News of MOLN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.